ExchangeDEX+
Buy CryptoMarketsSpotFuturesGOLDEarnEvent Center
More
HAIFA, Israel, Jan. 7, 2026 /PRNewswire/ — Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapiesHAIFA, Israel, Jan. 7, 2026 /PRNewswire/ — Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies

Remedy Cell Announces Initiation of Phase 1b Clinical Trial of RC-0315 in IPF Patients

Author: AI JournalSource: AI Journal
2026/01/07 21:31
Cellframe
CELL$0.0806-5.95%
Rebel Cars
RC$0.00409-0.96%
4
4$0.01518-1.62%

HAIFA, Israel, Jan. 7, 2026 /PRNewswire/ — Remedy Cell, a clinical-stage biopharmaceutical company focused on the development of proprietary cell-derived therapies for fibrotic diseases, today announces the initiation of “a partially-blinded randomized Phase 1b single and repeat dose (4-cohort) safety & tolerability study of RC-0315/Placebo administered intra-bronchially to idiopathic pulmonary fibrosis patients.”

The primary objective of the RC-0315 First-in-Human, Phase 1b clinical study is to measure drug safety and tolerability. The study’s exploratory objectives will assess the effect of RC-0315 on disease pathology, measured through imaging and biomarker analysis in bronchoalveolar lavage (BAL) and plasma samples.  

Idiopathic pulmonary fibrosis (IPF) is a fatal, highly complex and progressive interstitial lung disease affecting approximately 3 million people worldwide. With a survival of only 2-5 years post-diagnosis, it is characterized by interstitial lung tissue becoming thick and stiff with an excessive buildup of collagen. The degenerative progression of the condition results in a steady deterioration of lung function, escalating respiratory failure, and a significant reduction in overall quality of life. Despite the considerable impact of these diseases, current therapeutic options remain limited in both efficacy and scope, creating an urgent need for innovative approaches.

RC-0315 has the potential to fulfil this unmet clinical need by reducing fibrosis burden, repairing lung tissue damage, and restoring pulmonary function. It is a novel multifactorial, multi-proteinacious therapy that targets multiple IPF-associated targets simultaneously. RC-0315 therapeutic effect is attributed to its multi-target approach which enables a regenerative solution for complex fibrotic conditions.

Ayelet Dilion Mashiah, CEO, Remedy Cell, said: “Advancing our breakthrough platform into the clinic represents a significant milestone for Remedy Cell and offers hope for patients with IPF and their families. We believe our approach addresses the complexity of this disease and has the potential to support restoration of lung function.”

About Remedy Cell

Remedy Cell is a clinical stage biopharmaceutical company revolutionizing fibrotic disease treatment with cell-derived, cell-free breakthrough therapies. The company’s proprietary Activated Remedy Cell Secretome (ARcS) platform delivers multi-target, pro-regenerative solutions for complex fibrotic conditions. The company’s lead product, RC-0315, a first-in-class activated MSC-derived secretome therapy for IPF, has shown in definitive preclinical studies the potential to repair lung tissue and restore function. For more information, contact contact@remedycell.com.

Cision View original content:https://www.prnewswire.com/news-releases/remedy-cell-announces-initiation-of-phase-1b-clinical-trial-of-rc-0315-in-ipf-patients-302655070.html

SOURCE Remedy Cell

Market Opportunity
Cellframe Logo
Cellframe Price(CELL)
$0.0806
$0.0806$0.0806
+2.41%
USD
Cellframe (CELL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Channel Factories We’ve Been Waiting For

The Channel Factories We’ve Been Waiting For

The post The Channel Factories We’ve Been Waiting For appeared on BitcoinEthereumNews.com. Visions of future technology are often prescient about the broad strokes while flubbing the details. The tablets in “2001: A Space Odyssey” do indeed look like iPads, but you never see the astronauts paying for subscriptions or wasting hours on Candy Crush.  Channel factories are one vision that arose early in the history of the Lightning Network to address some challenges that Lightning has faced from the beginning. Despite having grown to become Bitcoin’s most successful layer-2 scaling solution, with instant and low-fee payments, Lightning’s scale is limited by its reliance on payment channels. Although Lightning shifts most transactions off-chain, each payment channel still requires an on-chain transaction to open and (usually) another to close. As adoption grows, pressure on the blockchain grows with it. The need for a more scalable approach to managing channels is clear. Channel factories were supposed to meet this need, but where are they? In 2025, subnetworks are emerging that revive the impetus of channel factories with some new details that vastly increase their potential. They are natively interoperable with Lightning and achieve greater scale by allowing a group of participants to open a shared multisig UTXO and create multiple bilateral channels, which reduces the number of on-chain transactions and improves capital efficiency. Achieving greater scale by reducing complexity, Ark and Spark perform the same function as traditional channel factories with new designs and additional capabilities based on shared UTXOs.  Channel Factories 101 Channel factories have been around since the inception of Lightning. A factory is a multiparty contract where multiple users (not just two, as in a Dryja-Poon channel) cooperatively lock funds in a single multisig UTXO. They can open, close and update channels off-chain without updating the blockchain for each operation. Only when participants leave or the factory dissolves is an on-chain transaction…
Share
BitcoinEthereumNews2025/09/18 00:09
Shanghai residents flock to sell gold as its price hit record highs

Shanghai residents flock to sell gold as its price hit record highs

The post Shanghai residents flock to sell gold as its price hit record highs appeared on BitcoinEthereumNews.com. Gold surged over the $5,500-per-ounce milestone
Share
BitcoinEthereumNews2026/01/31 01:48
Polygon Tops RWA Rankings With $1.1B in Tokenized Assets

Polygon Tops RWA Rankings With $1.1B in Tokenized Assets

The post Polygon Tops RWA Rankings With $1.1B in Tokenized Assets appeared on BitcoinEthereumNews.com. Key Notes A new report from Dune and RWA.xyz highlights Polygon’s role in the growing RWA sector. Polygon PoS currently holds $1.13 billion in RWA Total Value Locked (TVL) across 269 assets. The network holds a 62% market share of tokenized global bonds, driven by European money market funds. The Polygon POL $0.25 24h volatility: 1.4% Market cap: $2.64 B Vol. 24h: $106.17 M network is securing a significant position in the rapidly growing tokenization space, now holding over $1.13 billion in total value locked (TVL) from Real World Assets (RWAs). This development comes as the network continues to evolve, recently deploying its major “Rio” upgrade on the Amoy testnet to enhance future scaling capabilities. This information comes from a new joint report on the state of the RWA market published on Sept. 17 by blockchain analytics firm Dune and data platform RWA.xyz. The focus on RWAs is intensifying across the industry, coinciding with events like the ongoing Real-World Asset Summit in New York. Sandeep Nailwal, CEO of the Polygon Foundation, highlighted the findings via a post on X, noting that the TVL is spread across 269 assets and 2,900 holders on the Polygon PoS chain. The Dune and https://t.co/W6WSFlHoQF report on RWA is out and it shows that RWA is happening on Polygon. Here are a few highlights: – Leading in Global Bonds: Polygon holds 62% share of tokenized global bonds (driven by Spiko’s euro MMF and Cashlink euro issues) – Spiko U.S.… — Sandeep | CEO, Polygon Foundation (※,※) (@sandeepnailwal) September 17, 2025 Key Trends From the 2025 RWA Report The joint publication, titled “RWA REPORT 2025,” offers a comprehensive look into the tokenized asset landscape, which it states has grown 224% since the start of 2024. The report identifies several key trends driving this expansion. According to…
Share
BitcoinEthereumNews2025/09/18 00:40